Correlation between aryl hydrocarbon receptor and IL-17
Foxp3+ regulatory T
T helper 17
aryl hydrocarbon receptor
bladder cancer
Journal
International journal of experimental pathology
ISSN: 1365-2613
Titre abrégé: Int J Exp Pathol
Pays: England
ID NLM: 9014042
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
08
01
2021
received:
10
01
2020
accepted:
21
01
2021
pubmed:
12
11
2021
medline:
16
12
2021
entrez:
11
11
2021
Statut:
ppublish
Résumé
Bladder cancer (BC) is one of the most prevalent cancers around the world and, if not treated well, has high morbidity and mortality. Many studies have indicated that there may be various roles for the aryl hydrocarbon receptor (AHR) in the immune system. The aim of this study was to determine the frequency of Foxp3
Identifiants
pubmed: 34762773
doi: 10.1111/iep.12392
pmc: PMC8626624
doi:
Substances chimiques
FOXP3 protein, human
0
Forkhead Transcription Factors
0
Interleukin-17
0
Receptors, Aryl Hydrocarbon
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-259Informations de copyright
© 2021 Company of the International Journal of Experimental Pathology (CIJEP).
Références
Clin Cancer Res. 2003 Oct 1;9(12):4404-8
pubmed: 14555512
Trends Immunol. 2016 Jan;37(1):17-31
pubmed: 26700314
Cancer Immunol Immunother. 2020 Sep;69(9):1855-1867
pubmed: 32367308
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Blood. 2009 Aug 6;114(6):1141-9
pubmed: 19470694
Cancer Immunol Res. 2019 Jul;7(7):1175-1187
pubmed: 31160277
Clin Exp Immunol. 2010 Sep;161(3):480-9
pubmed: 20646003
Nature. 2008 May 1;453(7191):106-9
pubmed: 18362914
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238
pubmed: 30054281
Autoimmun Rev. 2014 Jun;13(6):668-77
pubmed: 24418308
Exp Cell Res. 2016 May 1;343(2):126-134
pubmed: 26973338
Genome Med. 2017 Jan 27;9(1):10
pubmed: 28129791
Urology. 2005 Dec;66(6 Suppl 1):4-34
pubmed: 16399414
Heliyon. 2020 Dec 01;6(12):e05556
pubmed: 33305045
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
Int J Exp Pathol. 2021 Dec;102(6):249-259
pubmed: 34762773
Neoplasia. 2010 Jun;12(6):434-42
pubmed: 20563246
J Immunol. 2001 Mar 15;166(6):3789-96
pubmed: 11238621
Nat Immunol. 2010 Sep;11(9):846-53
pubmed: 20676092
Int Immunopharmacol. 2014 Feb;18(2):255-61
pubmed: 24345703
J Immunol. 2005 Nov 1;175(9):6177-89
pubmed: 16237115
J Exp Med. 1999 Mar 1;189(5):753-6
pubmed: 10049938
J Immunol. 2010 Sep 15;185(6):3190-8
pubmed: 20720200
Anticancer Res. 2020 Mar;40(3):1345-1357
pubmed: 32132031
Immunol Lett. 2013 Jan;149(1-2):123-33
pubmed: 23159638
Eur Urol. 2018 Dec;74(6):784-795
pubmed: 30268659
BMC Cancer. 2020 Sep 9;20(1):869
pubmed: 32907554
Hum Immunol. 2013 Oct;74(10):1258-62
pubmed: 23827655
J Exp Med. 2001 Sep 3;194(5):629-44
pubmed: 11535631
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Oncol Rep. 2011 May;25(5):1271-7
pubmed: 21369705
Urol Oncol. 2017 Jan;35(1):14-20
pubmed: 27816403